Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma.

Abstract

The antibody-based targeted delivery of bioactive molecules to tumor vasculature is an attractive avenue to concentrate therapeutic agents at cancer sites, while sparing normal organs. L19, F8 and F16 are clinical-stage human monoclonal antibodies, which selectively recognize splice isoforms of fibronectin and tenascin-C in the modified extracellular matrix of neoplastic lesions. Here, we report the first comparative immunohistochemical analysis of L19, F8 and F16 in human Hodgkin and non-Hodgkin lymphomas. F16 was found to strongly stain the majority of lymphomas but also specimens of nonspecific lymphadenitis. By contrast, L19 exhibited a better discrimination between tumoral and inflammatory processes, yet at the expense of a weaker staining of the majority of lymphoma specimens investigated. The staining patterns observed for F8 were intermediate between the ones observed for L19 and F16. This study provides a rationale basis for the clinical investigation of therapeutic derivatives of the three antibodies in lymphoma patients.

• Authors: Christoph Schliemann, Andrea Wiedmer, Marta Pedretti, Monika Szczepanowski, Wolfram Klapper, Dario Neri
• Journal: Leukemia research (Leuk Res) Vol. 33 Issue 12 Pg. 1718-22 (Dec 2009) ISSN: 1873-5835 [Electronic] England
• PMID: 19625084 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Fibronectins
• Protein Isoforms
• Tenascin
• oncofetal fibronectin

Topics

• Antibodies, Monoclonal (immunology)
• Fibronectins (immunology, metabolism)
• Humans
• Immunohistochemistry
• Lymphoma (metabolism)
• Protein Isoforms (immunology, metabolism)
• Tenascin (immunology, metabolism)